Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | IDE | P14735 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | HLCS | P50747 | 5/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.51 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.51 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.51 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13225457 | 0.85 | TDP1 (0.60) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL13167087 | 0.83 | TDP1 (0.55) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL2607879 | 0.83 | TDP1 (0.58) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL420464 | 0.81 | TDP1 (0.72) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL22769273 | 0.81 | FOLH1 (0.69) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL2359254 | 0.81 | HLCS (0.65) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL12410184 | 0.81 | HLCS (0.53) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL2359251 | 0.80 | HLCS (0.56) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL903553 | 0.80 | TDP1 (0.83) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL2607878 | 0.79 | TDP1 (0.53) | TDP1PKMMEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283430-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170283430-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE | ABL1, BTK, LYN | TDP1 239/4885PKM 1330/4885MEN1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.